Table 1 Clinical data of hepatic epithelioid hemangioendothelioma patients
Patient | Age | Gender | Follow-up duration (months) | Number of tumor | Metastasis | Pathology | Treatment | Recurrence |
|---|---|---|---|---|---|---|---|---|
1 | 35 | Male | 60 | 1 | No | CD31(+), CD34(+), ERG(+), TFE-3(+), Ki67 (LI: approximately 5%) | LH | No |
2 | 43 | Male | 48 | 2 | Lymph nodes | CD31(+), CD34(+), ERG(+),PCK(+), Ki67 (LI: approximately 10%) | LH + RFA + lymphadenectomy | Yes |
3 | 67 | Female | 48 | 1 | No | CD31(+), CD34(+), ERG(+), TFE-3(+), Ki67 (LI: approximately 5%) | LH | No |
4 | 41 | Male | 42 | 1 | No | LH + RFA | No | |
5 | 28 | Female | 42 | 2 | Lymph nodes | CD31(+), CD34(+), ERG(+), FLi-1(+), Ki67 (LI: <5%) | LH + lymphadenectomy | Yes |
6 | 22 | Male | 36 | 1 | No | CD31(+), CD34(+), ERG(+), Ki67 (LI: approximately 5%) | LH + Huaier granule | No |
7 | 53 | Male | 36 | 2 | No | CD31(+), CD34(+), ERG(+), PCK(+), Ki67 (LI: approximately 5%) | LH + sorafenib + Huaier granule | No |
8 | 39 | Female | 24 | 1 | No | CD31(+), CD34(+), ERG(+), FLi-1(+), Ki67 (LI: <5%) | LH | No |
9 | 28 | Male | 12 | 3 | Gallbladder | CD31(+), CD34(+), ERG(+), PCK(+), Ki67 (LI: approximately 5%) | LH + RFA + cholecystectomy + chemotherapy + sorafenib + Huaier granule | No |
10 | 55 | Female | 12 | 2 | Lymph nodes | CD31(+), CD34(+), ERG(+), Ki67 (LI: approximately 15%) | LH + RFA + lymphadenectomy + sorafenib + Huaier granule | No |
11 | 55 | Male | 9 | 1 | No | CD31(+), CD34(+), ERG(+), TFE-3(+), Ki67 (LI: approximately 5%) | LH + sorafenib + Huaier granule | No |